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Abstract
We have studied the regulation and role of c-Myc and
Max in the differentiation pathways induced in K562
cells by 12-O-tetradecanoyl phorbol-13 acetate (TPA)
and staurosporine, an activator and inhibitor,
respectively, of protein kinase C (PKC). We found that
staurosporine induced megakaryocytic differentiation,
as revealed by the cellular ultrastructure, platelet
formation, and DNA endoreduplication. In contrast,
TPA induced a differentiated phenotype that more
closely resembled that of the monocyte-macrophage
lineage. c-myc expression was down-regulated in K562
differentiated by both TPA and staurosporine, whereas
max expression did not change in either case.
Although PKC enzymatic activity was low in cells
terminally differentiated with TPA and staurosporine,
inhibition of PKC activity by itself did not induce c-myc
down-regulation. We conclude that the c-myc gene is
switched off as a consequence of the differentiation
process triggered by these drugs in a manner
independent from PKC. Ectopic overexpression of c-
Myc in K562 cells did not affect the monocytic-
macrophagic and megakaryocytic differentiation,
indicating that c-Myc suppression is not required for
these processes in K562. Similarly, both differentiation
pathways were not affected by Max overexpression or
by concomitant overexpression of c-Myc and Max. This
result is in contrast with the inhibition of erythroid
differentiation of K562 exerted by c-Myc, suggesting
divergent roles for c-Myc/Max, depending on the
differentiation pathway.
Introduction
c-Myc is a nuclear protein of the helix-loop-helix/leucine
zipper family that acts as a transcription factor involved in the
control of cell proliferation, differentiation, and apoptosis
(1–4). c-Myc heterodimerizes through its leucine zipper do-
main with the protein Max (5, 6). Myc/Max heterodimers
transactivate gene expression upon binding to a specific
DNA sequence (E box). The interaction with Max is required
for all of the biological effects of c-Myc described hitherto. A
number of genes have found to be directly regulated by
c-Myc, including some involved in cell cycle control, nucleic
acid synthesis, and glucose metabolism (7, 8), but most of
the complex biological effects exerted by c-Myc are still
unexplained. Although expression of max is constitutive in
most systems, c-myc is subjected to extensive regulation
during growth and differentiation. The c-myc gene is highly
expressed in proliferating cells and is down-regulated during
cellular terminal differentiation (1, 2).
A model system extensively used to study the role of
c-Myc in differentiation is the chemically induced differenti-
ation of human myeloid cell lines. In cell lines such as U937,
HL60, HEL, and BM-02, the phorbol ester TPA3 inhibits
growth and induces differentiation into several phenotypes
of the myeloid lineage, and in all cases, differentiation is
accompanied by c-myc down-regulation (9–12). In contrast,
no major modification on max expression has been found in
the cell lines tested (13–15). Because TPA is a PKC activator,
the involvement of this family of enzymes in differentiation of
hemopoietic cells has received much attention (16). Differ-
ential roles for PKC isoforms in myeloid cell differentiation
have been reported for human and chicken cells (17–19).
TPA-induced differentiation of the human cell lines HL60,
HEL, and K562 has been attributed to PKC activation exerted
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by this drug (17, 20–22). However, there is confusion about
whether c-myc down-regulation observed during TPA-
induced differentiation is attributable to the activation of
PKC, as suggested in some reports (23–25), or rather is a
consequence of the cell differentiation process triggered by
the drug. In support of the latter idea, spontaneous differen-
tiation of HL60 upon reduction of c-myc expression has been
described (26–28).
We have investigated the involvement of c-myc and max in
the differentiation of K562 human myeloid cells triggered by
modifiers of PKC activity. Because the past studies were
hampered by the use of unipotent cell lines, we have ad-
dressed this problem by using a multipotent myeloid cell line,
which allows the comparison of the role of c-Myc in several
differentiation pathways of the same cell line. Human leuke-
mia K562 cells can be differentiated into erythroid cells by
1-b-D-arabinofuranosylcytosine (29, 30) or into myelomono-
cytic cells, expressing megakaryocytic, granulocytic, and
monocytic markers, by TPA (31–34). We showed previously
that ectopic c-myc expression impaired erythroid differenti-
ation (15), whereas max overexpression increased it (35). We
report here that the PKC inhibitor STA induces a clear
megakaryocytic phenotype in K562, distinct from that in-
duced by TPA, and we used this model to analyze the reg-
ulation and role of c-myc and max in monocyte-macrophagic
and megakaryocyte differentiation pathways. We found that
down-regulation of c-myc is linked to differentiation but in-
dependently of PKC activity. In contrast to their effects on
erythroid differentiation, ectopic expression of c-myc and
max does not modify the megakaryocytic and monocytic-
macrophagic differentiation pathways.
Results
Distinct Differentiation Phenotypes Induced by TPA and
STA in K562 Cells. Treatment of K562 cells with either TPA
or STA resulted in cell growth arrest, although with different
kinetics. Dose-response assays with STA demonstrated that
cell growth arrest and differentiation (described below) were
effectively at concentrations .50 nM (Fig. 1A). Transient ex-
posure to 100 nM STA for at least 8 h was required to
irreversibly arrest and differentiate the cells (see below; Fig.
1B). TPA was able to induce growth arrest and differentiation
of K562 cells at concentrations of 2.5 nM and above (Fig. 1C).
Concentrations of 10 nM TPA were chosen for additional
experiments. In contrast to the prolonged exposure required
for STA-mediated differentiation, treatment with 10 nM TPA
for just 30 min induced growth arrest and terminal differen-
tiation (Fig. 1D).
TPA treatment committed K562 cells into a well-known
phenotype, with loss of the expression of erythroid mark-
ers (fraction of cells positive for benzidine reaction and
expression of globins) and expression of a series of myeloid-
specific markers (33, 36). These include some typical
monocyte-macrophage markers such as expression of
CD14, phagocytosis, adherence to surfaces and cell clus-
ter formation, positive for ANAE and NBT reduction tests,
in addition to markers characteristic of megakaryocytes,
such as the expression of glycoproteins IIb-IIIa (CD41-
CD61; Table 1). On the other hand, cells treated with STA
for 3 days exhibited a phenotype that shared many char-
acteristics with those cells treated with TPA, including the
differentiation markers cited above and other less specific
markers as vimentin and c-fos expression (Table 1). How-
ever, significant morphological differences were observed
Fig. 1. Effect of STA (A and B)
and TPA (C and D) on cell growth
of K562 cells. Growth was deter-
mined by counting cell numbers
after incubation in the presence
of different concentrations of the
drugs (A and C) and after tran-
sient exposure to 100 nM STA (B)
and 10 nM TPA (D) for the indi-
cated periods of time. Cell den-
sity at the time of drug addition
was 250,000 cells/ml. Results
are mean values of three inde-
pendent experiments. SDs were
below 1 3 105 cells/ml for all
points.
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between TPA- and STA-treated cells after Giemsa stain-
ing, as shown in Fig. 2. Control cells exhibited a homoge-
neous population of round-shaped cells ;8 –10 mm of
diameter. The cell nuclei showed a round or oval shape
with one or two nucleoli. TPA-treated cells were more
heterogeneous. After 3 days of treatment with 10 nM TPA,
a majority of cells (58%; Table 1) showed a monocytic-
macrophagic morphology, with a higher cytoplasm:nu-
cleus ratio, eccentrically located reniform nuclei, and an
irregular cell surface due to projection of lamellipodia (Fig.
2C). A smaller fraction of megakaryocytic-like cells were
also observed in TPA-treated cells. This fraction ac-
counted for 18% (mean value from five independent ex-
periments) after 3 days of treatment with 10 nM TPA. The
rest of the cells retained blastic morphology (Fig. 1D).
Surprisingly, treatment with STA resulted in the appear-
ance of previously unreported megakaryocyte morphology
in most of the cells. These cells were characterized by their
large size (;30 –50 mm of diameter) and by the presence
of a highly lobulated nuclei, giving the appearance of
multiple nuclei after Giemsa staining (Fig. 2, E and G). The
fraction of multinucleated cells after STA treatment was
close to 100% in some experiments (Table 1). After 5 or
more days of treatment with STA, platelet-like bodies
could be seen in the cell cytoplasm (Fig. 2G) as well as in
the extracellular media. Both TPA- and STA-treated cells
formed clusters (Fig. 2, D and F) and adhered to plastic,
probably due to the expression of adhesion molecules in
the cell surface. However, TPA induced the appearance of
fibroblast-like cells (Fig. 2D), which were not seen in STA-
treated cultures. The cells with megakaryocytic morphol-
ogy tested negative for the ANAE cytochemical reaction
(Fig. 2I), which was in contrast with the strong positivity
found in TPA-treated cells (Fig. 2H). When the STA treat-
ment was prolonged for .3 days, an increasing number of
apoptotic cells appeared (19% after 6 days with 100 nM
STA; mean from three independent experiments). These
apoptotic figures were not seen in TPA-treated cells and
are consistent with the recent characterization of the ter-
minal differentiation of megakaryocytes as an apoptotic-
like process (37, 38).
To confirm the megakaryocytic phenotype of STA-
treated K562 cells, we performed ultrastructural analysis.
Untreated cells showed the characteristic morphology of
myeloid lineage blasts (Fig. 3A). The nucleus contained
small compact nucleoli and displayed numerous irregular
clumps of condensed chromatin along the nuclear enve-
lope. The perinuclear cytoplasm usually exhibited a cen-
trosomic area with a pair of centrioles, in addition to
cisterns of rough endoplasmic reticulum (Fig. 3B). The
cytoskeletal organization was characterized by the pres-
ence of focal accumulations of intermediate filament bun-
dles at the marginal cytoplasm (Fig. 3C). After TPA treat-
ment (10 nM; 96 h), the ultrastructural appearance of the
majority of the cells was macrophage like. The cell nucleus
was eccentrically located, with small aggregates of con-
densed chromatin associated with the nuclear envelope
and nucleolar periphery, as well as extensive domains of
dispersed chromatin and large compact nucleoli. The cy-
toplasm was endowed with phagosomes, lysosomes, lipid
droplets, and rough endoplasmic reticulum cisterns (Fig.
3D). Also of note was the presence of a prominent network
of intermediate filaments running through the cytoplasm,
particularly around the nuclei (Fig. 3E) and in the cell
periphery (Fig. 3F). After STA treatment (100 nM; 96 h),
most of the cells underwent a dramatic morphological
transformation to give megakayocytic cytological features.
As such, the cells became large and multinucleated or with
highly lobulated nuclei. The nuclei had a predominant
pattern of dispersed chromatin with small masses of het-
erochromatin forming a discontinuous band at the nuclear
periphery, in addition to one prominent nucleolus (Fig. 3G).
The central zone of the cytoplasm showed parallel arrays
of channels bounded by endomembranes lacking associ-
ated ribosomes (Fig. 3, H and I). This system of endomem-
branes clearly resembled the demarcation membranes ob-
served in mature megakaryocytes (39). The intermediate
filaments formed a network in the central area of the
cytoplasm with prominent fascicles associated with the
nuclei (Fig. 3H) and running through cytoplasmic areas
occupied by demarcation membranes. Some vacuoles,
endocytic vesicles, and lysosomes were also observed at
the peripheral cytoplasm (Fig. 3G).
In view of the prominent presence of intermediate fila-
ments in both TPA- and STA-treated cells (Fig. 3, E and H,
respectively) and the induction of vimentin mRNA expres-
sion observed in both types of differentiation pathways
(Table 1), we asked whether the filaments observed in the
ultrastructural analysis could be formed by vimentin and
whether there are differences in the cellular distribution of
the filaments between cells differentiated with TPA and
STA. Vimentin immunostaining of untreated K562 cells
Table 1 Differentiation markers in K562 cells treated with TPA and
STA
The predominant morphology was determined by May-Gru¨nwald Gi-
emsa staining, and the figures are the mean values from five independent
experiments. Marker expression was scored after 3 days of treatment with
10 nM TPA or 100 nM STA. Pluses indicate the percentage of positive cells:
2, ,10%; 1, 10–30%; 11, 30–60%; 111, .60% positive cells. CD61
and CD14 expression were determined by flow cytometry. Cell adhesion
was scored by cluster formation. mRNA expression of vimentin, e-globin
(after 24 h of treatment), and c-fos (after 1 h) was determined by Northern
analysis, and pluses indicate their relative expression after film densitom-
etry.
Predominant
cytology
Control TPA STA
Myeloblastic
Monocytic-
macrophagic
(58 6 10%)
Megakaryocytic
(86 6 9%)
NBT reduction 2 11 11
ANAE reaction 2 11 2
Cell adhesion 2 11 111
Latex phagocytosis 2 11 11
CD61 2 111 11
CD14 1 11 11
Vimentin 1 11 111
c-fos 2 111 11
e-Globin 11 2 2
Glycophorin A 1 2 2
Benzidine staining 1 2 2
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revealed filaments distributed through the cytoplasm that
appeared to originate from a polar focus (Fig. 4A). In
TPA-treated cells, the vimentin pattern displayed a tangle
of thick immunostained filament bundles, in addition to
thinner fascicles of filaments encircling the cell bodies,
just beneath the cell membrane (Fig. 4B). Vimentin immu-
nostaining of cells treated with STA for 72 h was charac-
terized by the presence of a marked network of thick
filament fascicles concentrated at the central region of the
cell and around the nuclei, in contrast with the more dis-
persed pattern observed in TPA-treated cells (Fig. 4C).
Overall, vimentin immunostaining of STA-treated cells was
more intense than in TPA-treated cells, in agreement with
the mRNA expression data (Table 1).
Fig. 2. Cell morphology of K562 cells
untreated (A and B) and treated for 3
days with 10 nM TPA (C, D, and H) or 100
nM STA (E, F, and I), as indicated. A, C,
E, and G, cytocentrifuge preparations
stained by May-Gru¨nwald-Giemsa
method (3600). The cells appearing as
multinucleated or with polilobulated nu-
clei are evident after treatment with STA
but not with TPA. G, a representative cell
after 6 days of treatment with 100 nM
STA, showing platelet-like forms in the
cytoplasm (arrows; 31000). B, D, and F,
phase-contrast micrographs of the cul-
tures showing the clustering induced af-
ter 3 days of treatment with 10 nM TPA
(D) or 100 nM STA (F) in standard plastic
plates (3200). Inset in D, fibroblast-like
cells appearing after TPA treatment in
tissue-culture plates. H and I, cells sub-
jected to the ANAE test after 3 days of
treatment with 10 nM TPA (H) or 100 nM
STA (I). Arrows, some positive TPA-
treated cells. The negative ANAE reac-
tion is evident in the multinucleated
STA-treated cells.
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Because the morphological analysis after treatment with
STA revealed the presence of multinucleated cells resem-
bling megakaryocytes, we next asked whether these cells
were actually polyploid and underwent endoreduplication,
a hallmark of megakaryocytic differentiation. The degree
of polyploidization in differentiated K562 cells was deter-
mined by propidium iodide staining after incubation with
TPA or STA for 72 h. DNA analysis showed that the ma-
jority (60%) of TPA-treated cells corresponded to cells in
G0-G1 phase (2C DNA content), although a significant
population (26%) appeared to remain in G2 (Fig. 5A). In
contrast, more than 50% of STA-treated cells showed a
DNA content 4C or higher. In fact, 30% corresponded to
cells with 8C DNA content. Thus, K562 cells became
polyploid upon treatment with STA but not with TPA. To
determine the existence of active S phase, cells differen-
tiated by TPA or STA were incubated with BrdUrd for the
final 12 h of the 72-h treatment. As can be seen in Fig. 5B,
both control and STA-treated cells had incorporated
BrdUrd (stained cells over the background level). How-
ever, very few BrdUrd-positive cells were detected in TPA-
treated cells. Statistical analysis revealed that 25 and 40%
of control and STA-treated cells, respectively, showed
positive staining. Interestingly, 90% of BrdUrd-labeled
control cells corresponded to cells in the G1-S boundary,
whereas 95% of the BrdUrd-labeled STA-treated cells
corresponded to 4C and 8C DNA-containing cells. Thus, in
contrast to TPA-differentiated cells, STA-treated K562
cells undergo active endoreduplication. Altogether these
data indicate that STA-induced differentiation resembles
that of the megakaryocytic phenotype. Despite the induc-
tion of common markers, this differentiation pathway is
clearly distinguishable from that induced by TPA, which
resembles closer the monocytic-macrophagic.
Fig. 3. Electron micrographs of
K562 control cells (A–C), cells treated
with 10 nM TPA for 96 h (D–F), and
cells treated with 100 nM STA for 96 h
(G–I). A, overview of an untreated
K562 cell. The cell nucleus shows
thread-like masses of condensed
chromatin and small nucleoli (N).
38400. B, detail illustrating a centro-
somatic area adjacent to the cell nu-
cleus, which contains a pair of centri-
oles (arrowhead) and a lysosome (L).
332,000. C, detail shows a focal con-
centration of fascicles of intermediate
filaments at the marginal cytoplasm.
338,000. D, overview of a typical
TPA-treated cell with a macrophage-
like morphology. The nucleus is ec-
centrically located and presents nu-
cleolus (N), small clumps of
condensed chromatin at the nuclear
periphery, and an extensive central
area of dispersed chromatin. The cy-
toplasm shows phagolysosomes (Ph),
lipid droplets, and bundles of fila-
ments. 35500. E, detail of the perinu-
clear region of the cytoplasm contain-
ing small bundles of intermediate
filaments and a lysosome (L).
312,000. F, detail of the peripheral
ring of bundles of intermediate fila-
ments. 338,000. G, overview of a typ-
ical STA-treated cell. The cell has a
large size and shows a megakaryo-
cyte-like morphology. Several small
nuclei or nuclear lobules appear dis-
placed at the periphery of the cell
body, and in many of them, the nucle-
oli is apparent (arrowhead). Note the
presence of clear vacuoles and some
endocytic vesicles containing elec-
tron-dense particles beneath the cell
membrane. 34250. H, detail of the
central region of the cytoplasm, which
illustrates a lattice of narrow clefts
identified as demarcation channels.
Note the concentration of intermedi-
ate filaments around the nucleus.
328,000. I, detail of cytoplasmic
channels bounded by paired demar-
cation membranes that outlines round
or, most frequently, elongated small
areas of cytoplasm. 320,000.
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Regulation of c-myc and max Expression during
TPA- and Staurosporine-induced Differentiation. We
have reported previously that c-myc is down-regulated
during TPA-induced differentiation of K562 cells (15, 40).
We have compared the regulation of c-myc and max genes
during TPA and STA-mediated differentiation. As shown in
Fig. 6A, the expression of c-myc mRNA levels decreased
significantly after 12 h of treatment with TPA, at which
point the cells were irreversibly differentiated and were
almost undetectable after 5 days of treatment. A biphasic
regulation of c-myc during TPA-mediated differentiation of
HL60 cells, with a transient peak after 30 – 60 min of TPA
addition, has been described (24). However, we did not
detect such regulation in TPA-treated K562 cells (not
shown). c-Myc protein was also dramatically down-regu-
lated in TPA-differentiated cells (Fig. 6B). On the other
hand, max mRNA levels suffered a slight, transient down-
regulation after TPA addition, but fully differentiated cells
after 3 days of treatment showed no significant changes in
mRNA (Fig. 6A) and protein levels (Fig. 6B).
c-myc expression was also down-regulated during treat-
ment with STA at the mRNA and protein levels (Fig. 7). The
kinetics of c-myc down-regulation during STA treatment is
slower than that induced by TPA treatment, as judged by
Northern blot (Fig. 7A) and by immunoblot (Fig. 7B) analysis.
c-myc mRNA levels dropped by barely 2-fold after 1 day of
treatment and reached almost undetectable levels after 5
days. As in the case of TPA, the expression of max did not
change significantly during STA treatment (Fig. 7). We also
tested whether these treatments modify the phosphorylation
state of c-Myc and Max. We did not detect major changes on
phosphorylation levels of either protein by in vivo radiolabel-
ing and immunoprecipitation during TPA and STA treatment
(not shown).
Inhibition of PKC Activity Does Not Induce Differen-
tiation of K562 Cells and Does Not Modify c-myc and
max Expression. Although TPA is reported to be an ac-
tivator of PKC activity, STA inhibits PKC as well as other
kinases (41, 42). The finding that c-myc was down-regu-
lated during differentiation induced both by TPA and STA
suggested that the observed c-myc suppression was as-
sociated with differentiation rather than with PKC activity.
To test this possibility, we measured PKC enzymatic ac-
tivities during TPA- and STA-mediated differentiation. In
agreement with the described effect of both drugs, PKC
activity was suppressed by STA and was activated by TPA
addition, with maximum activity after 5 min (Fig. 8A). This
result is consistent with the PKC translocation detected
shortly after TPA addition described previously in K562
cells (43). We also determined PKC activity in cells irre-
versibly differentiated by both drugs, i.e., 24 h after drug
addition. Interestingly, in K562 cells treated with 10 nM
TPA for 24 h, PKC activity was found to be only 15% of
that detected in untreated cells (Fig. 8B) and similar to that
observed in cells treated with high TPA concentrations (1
mM), at which PKC-a, PKC-b, and PKC-e isoforms, known
to be expressed in K562 cells (43), are down-regulated
(41). Similar low PKC activities were found after 72 h of
treatment (not shown). Thus, treatment with either TPA or
STA resulted in repressed PKC activity in differentiated
cells, despite the initial PKC activation exerted by TPA.
The former result raised the possibility that c-myc down-
regulation and cellular differentiation were two processes
independently linked to the suppression of PKC activity. To
Fig. 4. Vimentin immunocytochemistry form control untreated K562 cells
(A), cells treated with 10 nM TPA for 72 h (B), and cells treated with 100 nM
STA for 72 h (C). Confocal microcoscopy images representing the pro-
jection of several Z sections are shown. Bar, 10 mm. A, untreated cell
showing the arrangement of vimentin filaments in a delicate network
through the cytoplasm, with a center of vimentin condensation in the cell
periphery. B, TPA-treated cells showing an eccentrically located tangle of
thick vimentin fascicles, in continuity with thinner fascicles that encircle
the cell bodies at the marginal cytoplasm. C, STA-treated cells showing
intense vimentin immunoreactivity in the central region of the cytoplasm.
It appears as a network of thick fascicles of filaments, particularly prom-
inent around the nuclei.
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explore this possibility, we first asked whether PKC down-
regulation was sufficient for the differentiation of K562. We
approached this question by using GFX, a more specific
inhibitor of PKC than STA (44). Treatment with 2 mM GFX
resulted in a 75% inhibition of PKC activity (Fig. 8B). How-
ever, GFX did not cause cell growth arrest nor induced any
sign of monocytic or megakaryocytic differentiation, and
GFX-treated cultures reached similar cell densities as un-
treated cells, around 12 3 105 cells/ml. We next analyzed the
effect of GFX on TPA-mediated differentiation of K562. Pre-
treatment for 1 h with GFX abolished the differentiation in-
duced by TPA, as shown by the absence of cell growth arrest
and inhibition of cluster formation (Fig. 9A). As expected,
preincubation with GFX for 1 h blocked TPA-induced PKC
activation (Fig. 8B). On the other hand, STA-induced differ-
entiation was not inhibited by GFX or TPA pretreatments (Fig.
9A). When STA was added prior to TPA treatment, the dif-
ferentiation phenotype observed was that of STA alone, with
.80% of cells with megakaryocytic morphology after 3 days
of treatment (not shown).
Expression of c-fos is reported to be induced by TPA in
most cells types, including K562 (45), and is considered a
molecular marker of PKC activity. Therefore, we analyzed
c-fos induction in K562 after treatment with TPA and STA.
Both drugs induce c-fos (Table 1), although with different
kinetics; its expression peaked 6 h after TPA addition and
1 h after STA addition (not shown). As shown in Fig. 9B,
preincubation with GFX 1 h before TPA addition blocked
the dramatic induction of c-fos expression elicited by TPA.
However, GFX did not block c-fos induction mediated by
Fig. 5. Flow cytometric analysis of DNA con-
tent and BrdUrd incorporation. K562 cells were
cultured in the absence of drugs (CONTROL) or
in the presence of 100 nM STA or 10 nM TPA for
72 h. Cell densities at the time of drug addition
were 250,000 cells/ml and reached about 1.2 3
106 cells/ml in the untreated culture. DNA con-
tent and BrdUrd incorporation were determined
as described in “Materials and Methods.” A, pro-
pidium iodide staining. Vertical axis, relative
number of cells. Horizontal axis, relative DNA
content/cell. Leftmost peak, cells with 2C DNA
content, corresponding to G1 phase. Middle
peak, cells with 4C DNA content, corresponding
to G2-M phase of diploid cells (control cells) and
to G1-S phase of tetraploid cells. Rightmost
peak, cells with 8C DNA content, corresponding
to octaploid cells. Cells in S phase appear be-
tween 2C and 4C peaks. B, BrdUrd immunoflu-
orescence and propidium iodide staining. Verti-
cal axis, relative BrdUrd labeling per cell.
Horizontal axis, relative DNA content/cell. Bar,
limit of background fluorescence, corresponding
to cells cultured in the absence of BrdUrd and
incubated with both primary and secondary an-
tibodies.
Fig. 6. c-myc and max expres-
sion in K562 cells treated with TPA.
A, expression of c-myc and max in
K562 cells during TPA treatment
was analyzed by Northern blot as
described in “Materials and Meth-
ods.” Cells were treated with 10 nM
TPA for the indicated periods of
time. Lane 0, control cells prior to
drug addition. The filter was con-
secutively hybridized to the indi-
cated probes. A picture of the filter
after transfer is shown to assess
the loading and integrity of the
RNAs. B, expression of c-Myc and
Max proteins in K562 cells during
TPA treatment was analyzed by im-
munoblot as described in “Materi-
als and Methods.” Cells were
treated with 10 nM TPA for the in-
dicated periods of time. Left, posi-
tion of molecular mass markers.
645Cell Growth & Differentiation
STA (Fig. 9B). Altogether, these results indicate that PKC
inhibition per se does not induce differentiation of K562
cells but are consistent with the hypothesis that TPA-
induced differentiation is mediated by PKC. Thus, the
observed down-regulation of PKC activity in TPA-treated
cells appears to be a late event in monocytic-macrophagic
differentiation of K562.
The expression of c-myc and max was studied in K562
cells treated with 2 mM GFX for up to 48 h. Northern blot
analysis revealed that the steady-state mRNA levels for both
genes did not vary significantly after 24 and 48 h of treatment
(Fig. 10A), when PKC activity decreased to about 35% of
control levels (Fig. 8B). A slight decrease in c-myc expression
was observed after 2 days, but a similar drop was also found
in nontreated cells. Thus, this decrease can be associated to
growth arrest occurring at high cell densities. Immunoblot
with anti-Myc and anti-Max antibodies confirmed that GFX
did not significantly decrease c-Myc and Max protein levels
(Fig. 10B). Therefore, we conclude that the inhibition of PKC
activity by itself does not modify c-myc expression in K562
cells.
Enforced c-Myc Expression Does Not Interfere with
Differentiation Induced by TPA or STA. In view of the
observed c-myc down-regulation after TPA and STA treat-
ments, we tested whether ectopic c-myc overexpression
had an effect on the differentiation elicited by both drugs.
To avoid differences due to individual behaviors of the
selected clones, we carried out this analysis on cells trans-
fected with an inducible c-myc gene. We used the KmycJ
cell line, a derivative of K562 expressing a zinc-inducible
c-myc (15). Induction of c-myc by addition of ZnSO4 re-
sulted in a marked expression of c-myc, detected at the
mRNA (Fig. 11A) and protein levels (Fig. 11B). The smaller
mRNA detected in the Northern blots reveals the expres-
sion of the exogenous c-myc gene, because the trans-
fected construct lacks the first untranslated exon (46). As
described previously (14, 46), enforced expression of c-
myc down-regulated the endogenous c-myc mRNA (Fig.
11A). This well-described effect occurs at the transcrip-
tional level (47), suggesting that the ectopically expressed
c-Myc is entering the nuclei of K562. To directly test this,
we performed immunocytochemistry with anti-c-Myc an-
tibody and found that c-Myc was present in the nuclei of
STA- and TPA-treated cells in the presence of zinc but
could not be detected when the cells were differentiated in
the absence of zinc (Fig. 11C).
We then analyzed whether c-myc overexpression im-
paired TPA-mediated differentiation. Cells were pretreated
with 75 mM ZnSO4 for 2 h to assure that c-myc expression
was elevated at the time of TPA addition and its expres-
sion levels maintained during the treatment. c-Myc over-
expression did not modify the differentiation induced by
10 nM TPA, as assessed by vimentin and CD61 expression,
NBT reduction assay (not shown), and cell morphology
and adherence (Fig. 11D), confirming previous results (15).
Similarly, c-Myc overexpression did not impair differenti-
ation induced by 2 nM TPA (not shown), the minimal dif-
ferentiation-inducing concentration (Fig. 1C). We next
studied whether c-myc overexpression modified the
megakaryocytic differentiation induced by STA (100 nM).
As confirmed by Northern (Fig. 11A) and immunoblot anal-
ysis (Fig. 11B), exogenous c-myc expression was clearly
induced by zinc. In the presence of STA, despite the
elevated levels of c-Myc, the cells showed a differentiated
phenotype almost identical to cells differentiated with STA
in the absence of zinc. This was assessed by cell mor-
phology, cluster formation (Fig. 11D), and expression of
markers as NBT reduction and vimentin and CD61 expres-
sion (not shown). Likewise, enforced expression of c-Myc
did not modify the differentiation induced by 50 nM STA,
the lowest concentration that brought about differentia-
tion. Similar results were obtained with KmycB, another
c-myc-transfected K562 subline (not shown). From these
experiments, we conclude that c-Myc down-regulation is a
Fig. 7. c-myc and max expression in K562 cells treated with STA. A, expression of c-myc and max mRNA in K562 cells during TPA treatment was analyzed
by Northern blot as described in “Materials and Methods.” Cells were treated with 100 nM STA for the indicated periods of time. Lane 0, control cells prior
to drug addition. The same filter was consecutively hybridized to the indicated probes. A picture of the filter after transfer is shown to assess the loading
and integrity of the RNAs. B, immunoblot of c-Myc and Max proteins in K562 cells treated with 100 nM STA for the indicated periods of time, and the blots
were incubated with anti-Myc and anti-Max antibodies. Left, position of molecular mass markers.
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consequence but does not play a determinant role in the
megakaryocytic and monocytic differentiation response of
K562 cells.
c-Myc requires dimerization with Max to be active (see
“Introduction”). Thus, we next tested whether the ectopic
overexpression of Max modifies STA- and TPA-mediated
differentiation. We used two K562 sublines in which the
expression of max is zinc inducible, Kmax12 and Kmax16
(35). After addition of 75 mM ZnSO4 and TPA (10 nM) or STA
(100 nM), we analyzed the differentiation by cell morphology,
adherence, and NBT reduction. In the presence of zinc,
expression of Max was induced, but there were no significant
differences in the extent of STA-mediated megakaryocytic
differentiation or TPA-mediated monocytic differentiation
with respect to untreated cells (not shown).
It was formally possible that the availability of Max pro-
tein was limiting in situations where c-Myc is induced. To
explore this possibility, we generated double transfectants
in which the expression of c-myc and max are both in-
duced by zinc. To do so, we transfected a K562 subline in
which expression of c-Myc is zinc inducible (KmycB; Ref.
15) with a construct carrying a zinc-inducible human max
Fig. 8. A, activation of PKC by
TPA in K562 cells. Cells were
treated in serum-free media with
10 nM TPA (M) or pretreated for 1 h
with 2 mM GFX prior to TPA addi-
tion to 10 nM (GFX1TPA; E). Cells
were harvested at different times,
and PKC was determined as indi-
cated in “Materials and Methods.”
B, PKC activity in K562 cells after
24 h of treatment with 10 nM TPA,
100 nM STA, 100 nM STA plus 10
nM TPA, and 2 mM GFX. As nega-
tive control, the cells were treated
for 16 h with 1 mM TPA to achieve
complete depletion of PKC. M,
measurements obtained in the
presence of the PKC pseudosub-
strate inhibitor. Bars, SD.
Fig. 9. Effect of GFX on the differen-
tiation of K562 cells induced by TPA
and STA. A, micrographs of the cells
taken at the indicated times of treat-
ment with 10 nM TPA, 100 nM STA, or
2 mM GFX (3100). 3d, 3 days. B, GFX
inhibits c-fos induction mediated by
TPA but not by STA. Cells were
treated for 1 h with 2 mM GFX (Lane
G), 1 h with 10 nM TPA (Lane T), 100
nM STA (Lane S), 1 h with 2 mM GFX
followed by 1 h with 100 nM STA (Lane
G1S), and 1 h with 2 mM GFX followed
by 1 h with 10 nM TPA (Lane G1T).
RNA was prepared, and expression of
c-fos mRNA was determined by
Northern blot.
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gene (pHEBo-MTmax; Ref. 35). Two transfectant cell lines
with zinc-inducible expression of c-myc and max mRNA,
termed Kmyma3 and Kmyma20, were selected (Fig. 12A),
and the overexpression of Max and c-Myc proteins upon
addition of ZnSO4 was verified by immunoblot (Fig. 12B).
Also, the expression of ectopic c-myc and max was in-
duced by 75 mM ZnSO4 in cells treated with 10 nM TPA or
100 nM STA, under which conditions endogenous c-myc is
repressed (Fig. 12A). We then tested the differentiation
response of Kmyma3 and Kmyma20 after treatment with
TPA or STA and found that the differentiation of both cell
lines was alike in the presence and absence of zinc. This
was assessed by cell morphology, and up-regulation of
vimentin and repression of e-globin (Fig. 12A), NBT cyto-
chemical reaction (not shown), and cluster formation (Fig.
12C). Similarly, enforced coexpression of c-Myc and Max
did not impair the differentiation achieved with lower drug
concentrations (2 nM TPA and 50 nM STA). We also gen-
erated a double transfectant in which Max expression was
zinc inducible, and high levels of constitutive c-myc ex-
pression were achieved by retroviral infection (LmycSN
vector). These cells showed a similar differentiation re-
sponse, regardless of the induction of max (not shown).
Altogether, these results indicate that overexpression of
c-Myc did not modify monocytic or megakaryocytic dif-
ferentiation of K562.
Discussion
The present work has established: (a) a new model of in vitro
megakaryocytic differentiation, i.e., K562 cells treated with
the PKC inhibitor staurosporine; (b) we show that, although
Max expression does not change, c-myc gene is down-
regulated during monocytic-macrophagic and megakaryo-
cytic differentiation of K562 in a PKC-independent manner;
(c) we show that PKC activity does not correlate with c-myc
expression levels in K562; and (d) we demonstrate that en-
forced expression of c-Myc and Max does not inhibit the
monocytic-macrophagic and megakaryocytic differentiation
induced by TPA or STA.
The differentiation phenotype induced by TPA in K562
cells is usually referred to as “megakaryocytic,” based on
the expression of markers such as CD41 (glycoprotein IIb),
CD61 (glycoprotein IIIa), and platelet-derived growth fac-
tor (33, 36). However, in contrast to a widely accepted
view, the majority of TPA-treated K562 cells resemble
monocytes-macrophages on the basis of cell morphology
and ultrastructure, albeit megakaryocyte-like cells are also
present. We have also found that treatment of K562 cells
with STA induced in most cells a differentiated phenotype
that strongly resembled megakaryocytes. Previous reports
have shown that STA induced polyploidy in K562 cells
(48), but the differentiation phenotype was reported to be
the same as that induced by TPA. This could be explained
by the fraction of megakaryocyte-like cells, which also
appear after TPA treatment, that may be partially respon-
sible for the similar pattern of surface marker expression
detected in STA- and TPA-differentiated cells. However,
we found that STA-treated cells show highly lobulated
nuclei, undergo active endoreduplication, and display de-
marcation membranes in cytoplasm. All these traits are
hallmarks of megakaryocytes. Furthermore, platelet-like
forms can be observed in the cytoplasm and conditioned
media of STA-treated cells. Other differences between
TPA- and STA-induced differentiation include the pattern
of distribution of vimentin filaments and the ANAE reaction
Fig. 10. myc and max expression is not modified in K562 cells treated with GFX. A, Northern analysis of RNAs isolated from cells treated with 2 mM GFX
for 1 and 2 days. Control lanes, cells without drug addition. The same filter was consecutively hybridized to the c-myc and max probes. A picture of the
filter after transfer is shown to assess the loading and integrity of the RNAs. B, immunoblot of proteins from cells treated with GFX. Cells were untreated
(control lanes) or treated with 2 mM GFX for the indicated periods of time. The blots were incubated with anti-Myc and anti-Max antibodies as indicated.
Left, position of molecular mass markers.
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(negative for STA-treated cells but positive for monocyt-
icTPA-differentiated cells). Finally, there are profound dif-
ferences in the differentiation kinetics induced by both
drugs, i.e., cells require longer exposure to STA than to
TPA to become committed. Therefore, K562 cells are a
unique model that can be directed into at least three
distinct types of differentiation (erythroid, megakaryocytic,
and monocytic-macrophagic). Moreover, the megakaryo-
cytic differentiation elicited by STA is not exclusive for the
K562 cell line, because STA also mediates megakaryo-
cytic differentiation in KU812 cells, another chronic mye-
loid leukemia cell line.4
Interestingly, the drugs used to induce monocytic or
megakaryocytic differentiation were an activator (TPA) and
an inhibitor (STA) of PKC. We took advantage of this model
to study the relationship between PKC and c-myc regula-
4 N. Ajenjo and J. Leo´n, unpublished observations.
Fig. 11. Enforced expression of c-Myc does
not modify differentiation induced by TPA and
STA in K562 cells. A, Northern analysis show-
ing induction of exogenous c-myc mRNA
upon zinc addition in KmycJ cells treated with
10 nM TPA or 100 nM STA and in the presence
or absence of 75 mM ZnSO4, as indicated. The
c-myc exogenous transcript is smaller be-
cause the transfected gene lacks the first un-
translated exon. B, immunoblot analysis
showing induction of c-Myc protein. KmycJ
cells were treated with TPA and STA in the
presence and absence of zinc as indicated
above, and the c-Myc levels were determined
by immunoblot. C, localization of c-Myc in
KmycJ cells treated for 72 h with 10 nM TPA or
100 nM STA in the presence or absence of 75
mM ZnSO4 as indicated. Immunocytochemis-
try was carried out with anti-c-Myc antibody
as described in “Materials and Methods.” c-
Myc is detected in the nuclei of cells differen-
tiated to monocytes (TPA) or megakaryocytes
(STA) in the presence of zinc. Note the staining
of the highly polilobulated nuclei of the STA-
treated cells. No staining was detected in cells
incubated with the secondary antibody alone
(not shown). D, micrographs of KmycJ cells
treated for 72 h with 75 mM ZnSO4 and 10 nM
TPA or 100 nM STA as indicated in each case.
Increase in cell adherence during differentia-
tion results in the formation of cell clusters. In
all of the experiments, ZnSO4 was added 2 h
before TPA or STA.
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tion, as well as the effect of c-myc overexpression on both
differentiation pathways. Similarly to many differentiation
models, c-myc expression is down-regulated during
monocytic macrophagic and megakaryocytic differentia-
tion. Conversely, max expression is kept constant in both
processes. These results suggest that the levels of tran-
scriptionally active Myc-Max complexes are low in K562
cells differentiated into monocyte-macrophages or
megakaryocytes, and that the majority of the Max proteins
would be either in Max-Max homodimers or complexed
with proteins of the Mad family (Mad1, Mxi1, Mad3, and
Mad4), as demonstrated in other differentiation models
(13, 14, 49, 50).
In all myeloid cell lines thus far investigated, the expression
of c-myc is suppressed upon differentiation induced by TPA
(9–12). The results of the present work extend this finding to
STA-mediated differentiation. The issue of whether the sup-
pression of c-Myc levels correlate with differentiation or with
PKC activity has been subjected to controversy, mostly
based on studies performed in HL60 cell lines (22–24). To
tackle this problem, we measured PKC activities in TPA- and
STA- treated K562 cells. As expected, STA inhibited PKC
activity and TPA activated PKC after short treatment times.
However, PKC activity was also low after 24 h of treatment
with TPA, when the cells are irreversibly growth arrested and
Fig. 12. Enforced coexpression of c-
Myc and Max does not modify the dif-
ferentiation induced by TPA and STA in
K562 cells. A, Northern analysis of c-
myc, max, vimentin, and e-globin of
Kmyma3 and Kmyma20 cells treated
with 10 nM TPA and 100 nM STA in the
absence and presence of 75 mM ZnSO4
as indicated. B, c-Myc and Max induc-
tion after zinc addition in Kmyma3 and
Kmyma20 cells. Cells were treated with
75 mM ZnSO4 for 1 and 2 days and the
levels of c-Myc and Max were deter-
mined by immunoblot. The same filter
was used consecutively for c-Myc and
Max detection. Only the p21 form of
Max was induced after zinc addition be-
cause this is the form encoded by the
transfected gene. C, micrographs of
Kmyma20 cells treated for 72 h with 75
mM ZnSO4, 10 nM TPA, and 100 nM STA,
as indicated in each case. Increase in
cell adherence during differentiation re-
sults in the formation of cell clusters. In
all of the experiments, ZnSO4 was
added 2 h before TPA or STA.
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differentiated. It is known that chronic exposure to TPA re-
sults in PKC down-regulation, although in other cell types as
murine fibroblasts (51) and chicken E26-infected myelo-
blasts (19), this effect requires much higher TPA concentra-
tions than in K562. Thus, our results opened the possibility
that the repression of c-myc expression is a consequence of
the PKC down-regulation, in agreement with previous re-
ports in HL60 cells (24, 25). However, the inhibition of PKC by
the specific inhibitor GFX did not provoke any effect on
growth and differentiation and did not down-regulate c-myc,
whereas it completely blocked TPA-mediated differentiation.
Altogether, our results indicate that: (a) the expression of
c-myc and max in K562 are unrelated to PKC activity but are
linked to the differentiation process; and (b) TPA induces
differentiation of K562 by a PKC-dependent mechanism.
Also, it must be noted that STA also inhibits other protein
kinases such as protein kinase A (41) and cyclin-dependent
kinase 2 (42); therefore, STA-mediated differentiation might
involve mechanisms other than PKC inhibition.
Constitutive overexpression of c-Myc inhibits differen-
tiation in most hematopoietic cell models analyzed, includ-
ing murine erythroid (52–54) and monocytic (55, 56) cell
lines. Supression of c-myc expression with antisense
mRNA or oligonucleotides (26 –28) results in spontaneous
differentiation of human HL60 cells, although these find-
ings have not been confirmed in other studies (57– 60). We
found that c-Myc does not play a role in K562 commitment
to myeloid differentiation, at least at the expression levels
achieved in the transfected cells. Although significant
amounts of c-Myc are present in the nuclei of transfected
cells, differentiated with TPA or STA, a possible explana-
tion for the lack of effect of c-Myc is that the total expres-
sion levels of c-Myc obtained in our transfectants are not
sufficient to achieve a differentiation block. Although this
possibility cannot be formally excluded, ectopic c-Myc
provokes down-regulation of endogenous c-myc mRNA
expression. Moreover, in the same cell lines, similar c-Myc
levels impair erythroid differentiation (15). Also, it could be
possible that Max concentration is a limiting factor for
c-Myc functions in this model. We ruled out this possibility
because double transfectants with concomitant induction
of Max and c-Myc are efficiently differentiated by TPA and
STA. Likewise, we found that Max overexpression alone
had no apparent effect on the differentiation induced by
STA and TPA.
There are several examples where enforced expression of
c-myc or v-myc do not inhibit terminal differentiation, such as
murine keratinocytes (57, 58), murine muscle cells (59, 60),
rat oligodendrocyte progenitors (61) and quail chondroblasts
(62), and mouse F9 teratocarcinoma cells (63). The present
study with K562 cells is the first report on a similar finding in
cells of myeloid lineage. Our results are in contrast with the
described inhibition by v-myc of TPA-mediated differentia-
tion of U937 (64). We do not know the reason for this differ-
ence, but it may reside in the different origin of these cell lines
(K562 derives from a chronic myeloid leukemia, whereas
U937 derives from a malignant histiocytosis) and the trans-
fected gene (v-myc in U937 and c-myc in K562). Conversely
to the monopotent U937 cells, K562 can be differentiated
toward erythroid, monocytic, and megakaryocytic lineages.
The fact that monocytic and megakaryocytic differentiation
are unaffected by c-Myc overexpression is in striking con-
trast with the partial inhibition of erythroid differentiation by
ectopic overexpression of c-myc (15). Thus, the K562 model
demonstrates diverging roles of the c-Myc/Max complex in
the control of the commitment to distinct differentiation lin-
eages in human myeloid cells.
Materials and Methods
Cell Culture and Transfections. K562 cell line was obtained from
American Type Culture Collection. Cells were grown in RPMI 1640
medium (Life Technologies, Inc., Gaithersburg, MD) supplemented with
8% FCS (Biochrome, Berlin, Germany) and gentamicin (80 mg/ml).
KmycB and KmycJ are cell lines described previously with inducible
expression of c-myc (15). Kmax12 is a cell line with inducible expres-
sion of max described previously (35). KmycB (2 3 106 cells) were
electroporated (260 V and 1 mF; Bio-Rad Gene Pulser apparatus) with
20 mg of pHEBoMT-max (35) and 5 mg of LXSN, a plasmid encoding
G418 resistance (65). After electroporation, cells were incubated for
48 h, and 0.5 mg/ml of G418 was added. Transfectant cell clones were
selected by limiting dilution. Cell densities were kept below 106/ml.
When indicated, exponentially growing cells at a concentration of 2.5 3
105 cells/ml were treated with TPA (Sigma, St. Louis, MO), STA (Roche
Molecular Biochemicals, Barcelona, Spain), or GFX (Calbiochem, Cam-
bridge, MA). Cell growth and viability were assayed by hemocytometer
and the trypan blue exclusion test.
Differentiation Marker Determinations. Morphological differenti-
ation was monitored by examining cell preparations stained with May-
Gru¨nwald Giemsa and assessed using established cytological criteria.
The fraction of hemoglobin-producing cells was scored by benzidine
staining as described previously (29). NBT dye reduction was used to
monitor monocyte/granulocytic differentiation (66). The presence of
ANAE (nonspecific esterase) was determined by cytochemistry with a
commercial kit (Sigma). The expression of cell surface markers was
measured by quantitative fluorescence analysis using an Epics Profile
II flow cytometer (Coulter Electronics). The cells were incubated for 45
min at 4°C with the appropriate monoclonal antibodies. At least 10,000
cells were analyzed for each antibody for light scattering and fluores-
cence intensity. The antibodies used were: anti-glycoprotein IIIa
(CD61) and CD14 (FITC-conjugated; Dako, Copenhagen, Denmark).
Nonspecific fluorescence was determined by using isotypic negative
control antibodies.
DNA Analysis by Flow Cytometry. To determine DNA content, cells
were collected by centrifugation, washed once in PBS, and resuspended
in citrate buffer (50 mM sodium citrate, 0.1 mg/ml RNase A, and 10 mg/ml
propidium iodide). After incubation at 37°C for 30 min, the stained cells
were analyzed in a FACScan flow cytometer (Becton Dickinson) using the
CellQuest software. To analyze the fraction of cells undergoing DNA
synthesis (S phase), cells were cultured in the presence of 20 mM BrdUrd
for 12 h. After fixation in 70% ethanol at 4°C for 15 min, the cells were
washed and resuspended in PBS. The genomic DNA was denaturated by
incubation of fixed cells in 1 N HCl-0.5% Tween 20 at 37°C for 15 min.
After centrifugation, cells were washed twice in PBS-2% FCS and incu-
bated with 50 ml of anti-BrdUrd monoclonal antibody (Amersham) diluted
in PBS-0.1% Triton X-100 for 20 min on ice. After washing in PBS-2%
FCS, cells were analyzed by flow cytometry in the presence of propidium
iodide as above.
Electron Microscopy. Cell pellets were fixed in freshly prepared 3%
glutaraldehyde in PBS for 60 min, dehydrated in acetones, and embedded
in araldite. Ultrathin sections were stained with uranyl acetate and lead
citrate and examined and photographed with a Phillips EM 208 electron
microscope.
Immunocytochemistry. Cytospin preparations were fixed in
freshly prepared 3.7% paraformaldehyde in PBS (pH 7.4) at room
temperature for 15 min with gentle agitation. For immunofluorescence,
the cells were made permeable in 0.2% Triton X-100 at room temper-
ature for 5 min and natural paraformaldehyde fluorescence was
blocked with 0.1 M glycine in PBS. After three washes in PBS-0.1%
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Tween 20 (PBS-T; 2–3 min each), the cells were incubated for 1 h at
room temperature with a monoclonal anti-vimentin antibody (V9;
Roche Molecular Molecular Biochemicals) diluted 1:10. The slides were
rinsed in PBS-T for 5 min and incubated for 45 min at room temperature
with an anti-mouse FITC-conjugated secondary (Vector, Burlingame,
CA) diluted 1:100. After washing with PBS, the samples were mounted
with Vectashield (Vector) and examined with a confocal laser micro-
scope (Bio-Rad 1024) using argon ion (488 nm) to excite FITC. For
c-Myc detection, cells were fixed with paraformaldehyde as above,
treated with 3% H2O2 in cold methanol, washed with PBS-T, and
incubated for 1 h with a monoclonal anti-c-Myc antibody (C-33, diluted
1:10; Santa Cruz Biotechnology, Santa Cruz, CA). The slides were
washed in PBS-T and incubated with biotinylated anti-mouse IgG and
ExtrAvidin peroxidase (Sigma) and revealed using 3,39-diaminobenzi-
dine as the peroxidase substrate.
RNA Analysis. Total RNA was isolated from cells by the acid guani-
dine thiocyanate method (67). RNA samples (15 mg/lane) were electro-
phoresed on 1% agarose-formaldehyde gels and transferred to nitrocel-
lulose membranes (Millipore, Bedford, MA) as described (68), except that
1 mg of ethidium bromide was added to each RNA sample prior to gel
loading. A picture of the filter under UV light was obtained after transfer to
assess the amount and integrity of the rRNAs. The Northern blots were
hybridized at 42°C in 40% formamide, 5% dextran sulfate, 0.8 M NaCl, 50
mM sodium phosphate (pH 7), 0.2% SDS, 150 mg of denatured salmon
sperm DNA/ml, and DNA probe labeled with [32P]dCTP by random primed
labeling (Pharmacia kit). The filters were washed to a final stringency of
0.53 SSC (0.15 M NaCl, 0.15 M sodium citrate) and 0.1% SDS at 65°C and
autoradiographed at 270°C. The signals were quantified with a Bio-Rad
Molecular Imager GS-250 apparatus. Probes for human c-myc, max,
e-globin, and vimentin were as described (15). Probe for human c-fos
probe was the 1.5-kb PstI fragment from pFOS-1 (obtained from American
Type Culture Collection).
Immunoblots. For c-Myc and Max determinations, cell pellets were
lysed in a solution containing 100 mM Tris (pH 6.8), 8% b-mercapto-
ethanol, 4% SDS, and 20% glycerol. The lysates were boiled for 5 min
and passed through 21-gauge needle to shear the DNA. Protein con-
tent was measured using Bio-Rad Protein Assay. Forty mg of protein/
lane were separated in 10% acrylamide gels and transferred to poly-
vinylidene difluoride membranes (Millipore), using a semidry
electroblotter (Millipore) and a buffer containing 10 mM Trizma, 96 mM
glycine, and 10% methanol. c-Myc protein was detected by the anti-
Myc antibody (1–9E10; Santa Cruz Biotechnology). Max was detected
with a rabbit polyclonal antibody (Upstate Biotechnology, Lake Placid,
NY). Proteins were detected by chemiluminescent (ECL; Amersham,
Buckinghamshire, United Kingdom).
PKC Activity Determinations. Cells incubated in the presence of
TPA or STA were harvested in a buffer containing 20 mM Tris (pH 7.5),
0.5 mM EDTA, 0.5 mM EGTA, 0.5% Triton X-100, 25 mg/ml leupeptin, 25
mg/ml aprotinin, and 10 mM b-mercaptoethanol. Cells were disrupted
by passage through a 26-gauge needle and centrifuged for 15 min at
4 C at 12,000 3 g. Protein concentration in the supernatants was
determined by the Bio-Rad kit. PKC activity was determined using a kit
(Life Technologies, Inc.) essentially as described by the manufacturers
without adding TPA or phosphatidylserine-containing liposomes. PKC
activity in cell extracts was determined by measuring phosphotrans-
ferase activity to a synthetic peptide derived from myelin basic protein
(69). The reaction was carried out with 4 mCi/ml [g-32P]ATP, 20 mM ATP,
20 mM MgCl2, and 1 mM CaCl in the presence or absence of 20 mM
pseudosubstrate peptide PKC (19 –36), a potent inhibitor of PKC (max-
imal activity on a, b, and g isoforms) used as a control for PKC
specificity of the assay (70).
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